OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for AM26225FC-N

Complement C9 (C9) Mouse Monoclonal Antibody [Clone ID: aE11]

Product data:

Product Type:	Primary Antibodies
Clone Name:	aE11
Applications:	ELISA, FN, IF, IHC
Recommended Dilution:	Immunohistochemistry on frozen sections (6): The typical starting working dilution is 1:50. Immunohistochemistry on paraffin sections (4): The typical starting working dilution is 1:50. Flow cytometry (5): The typical starting working dilution is 1:50. Functional assays (3,5). Immunoassays (1,2). Immunoflourescence (2,4). Positive control: Mucosa from patients with H. Pylori. Does not work in Western blot (2).
Reactivity:	Equine, Human, Porcine
Host:	Mouse
Isotype:	IgG2a
Clonality:	Monoclonal
Specificity:	Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC).
Formulation:	PBS Label: FITC State: Liquid 0.2 µm filtered Ig fraction Stabilizer: 0.1% bovine serum albumin Preservative: 0.02% sodium azide
Concentration:	lot specific
Purification:	Protein G
Conjugation:	FITC
Storage:	Store at 2 - 8 °C.
Stability:	Shelf life: one year from despatch.
Gene Name:	complement component 9

View online »

Database Link: Entrez Gene 735 Human
P02748

Background: The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

Synonyms: Complement component C9, Complement 9